Get started
Author

Ibón Gutierro

Observed names: I Gutierro, I. Gutierro, Ibon Gutierro, Ibón Gutierro Adúriz
ORCID: 0000-0002-7533-9194
Observed ORCID: 0000-0002-7533-9194
OpenAlex ID: A5067167326
Size dependent immune response after subcutaneous, oral and intranasal administration of BSA loaded nanospheres
2002 · I Gutierro, R.M Hernández, et al. · Vaccine · 293
Influence of dose and immunization route on the serum Ig G antibody response to BSA loaded PLGA microspheres
2002 · I Gutierro, R.M Hernández, et al. · Vaccine · 43
Phase I, open-label, randomized, parallel study to evaluate the pharmacokinetics, safety, and tolerability of one intramuscular injection of risperidone ISM at different dose strengths in patients with schizophrenia or schizoaffective disorder (PRISMA-1)
2016 · Jordi Llaudó, Lourdes Anta, et al. · International Clinical Psychopharmacology · 27
A phase II study to evaluate the pharmacokinetics, safety, and tolerability of Risperidone ISM multiple intramuscular injections once every 4 weeks in patients with schizophrenia
2017 · Lourdes A. Carabias, Jordi Llaudó, et al. · International Clinical Psychopharmacology · 24
The Steady-State Comparative Bioavailability of Intramuscular Risperidone ISM and Oral Risperidone: An Open-Label, One-Sequence Study
2021 · David P Walling, Howard A Hassman, et al. · Drug Design Development and Therapy · 20
PDF
Bioequivalence of a biosimilar enoxaparin sodium to Clexane® after single 100 mg subcutaneous dose: results of a randomized, double-blind, crossover study in healthy volunteers
2018 · Javier Martínez González, Mayte Monreal Núñez, et al. · Drug Design Development and Therapy · 12
PDF
Preliminary Assessment of the Immune Response toOlea europaeaPollen Extracts Encapsulated into PLGA Microspheres
2001 · M. Igartua, R. M. Hernández, et al. · Pharmaceutical Development and Technology · 12
Development of a population pharmacokinetic model for the novel long‐acting injectable antipsychotic risperidone ISM®
2024 · Christian Laveille, Eric Snoeck, et al. · British Journal of Clinical Pharmacology · 9
PDF
Pharmacodynamics assessment of Bemiparin after multiple prophylactic and single therapeutic doses in adult and elderly healthy volunteers and in subjects with varying degrees of renal impairment
2014 · Salvador Rico, Rosa-María Antonijoan, et al. · Thrombosis Research · 7
Exposure‐Efficacy Analysis and Dopamine D2 Receptor Occupancy in Adults with Schizophrenia after Treatment with the Monthly Intramuscular Injectable Risperidone ISM
2024 · Andreas Lindauer, Eric Snoeck, et al. · The Journal of Clinical Pharmacology · 6
PDF
Comparison of dopamine D2 receptor occupancy profiles between risperidone ISM versus oral risperidone and monthly paliperidone palmitate based on population pharmacokinetic modelling and simulations
2025 · Eric Snoeck, Nicolas Luyckx, et al. · Expert Review of Clinical Pharmacology · 4
Population pharmacokinetic modeling and simulations of dopamine Dd2 receptor occupancy of long-acting intramuscular risperidone-ISM
2016 · J. Llaudó, L. Anta, et al. · European Psychiatry · 3
PDF
Immune responses to orally administered PLGA microparticles: influence of oil vehicles and surfactive agents
2003 · I. Gutierro, R. M. Hernández, et al. · Journal of Microencapsulation · 3
Pharmacokinetics, safety, and tolerability of four 28-day cycle intramuscular injections for risperidone-ISM 75 mg in patients with schizophrenia: A phase-2 randomized study (PRISMA-2)
2016 · L. Anta, J. Llaudó, et al. · European Psychiatry · 2
PDF
Pharmacokinetic/pharmacodynamic modeling and simulation of dopamine D2-receptor occupancy-time profiles comparing monthly risperidone ISM versus monthly paliperidone palmitate
2023 · E. Snoeck, N. Luyckx, et al. · Neuroscience Applied · 1
Pharmacokinetic/pharmacodynamic modeling and simulation of dopamine D2-receptor occupancy-time profiles comparing Risperidone ISM versus daily oral risperidone
2023 · E. Snoeck, N. Luyckx, et al. · Neuroscience Applied · 1
The Steady-State Comparative Bioavailability of Intramuscular Risperidone ISM and Oral Risperidone: An Open-Label, One-Sequence Study [Corrigendum]
2022 · David P Walling, Howard A Hassman, et al. · Drug Design Development and Therapy · 1
PDF
Phase i clinical trialto evaluate the pharmacokinetics, safety, and tolerability of one intramuscular injection of risperidone ISM® at different dose strengths in subjects with Schizophrenia or Schizoaffective disorder (PRISMA-1)
2015 · J. Llaudó, I. Ayani, et al. · Clinical Therapeutics
PDF
C0304: Bemiparin Pharmacodynamics/Pharmacokinetics in Young, Elderly and Subjects with Renal Impairment
2014 · J. Martínez-González, S. Rico, et al. · Thrombosis Research
Works count: 19
Citation count: 468
H-index: 8
I10-index: 7
Year
Topic
Type